Attendees can expect to gain insight into the Company's business activities, clinical trials, and psychedelic drug development facility
Vancouver, British Columbia, July 19, 2021 – Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development, today announced that it will host a virtual investor event on Thursday, August 12, 2021 at 2:00 p.m. EDT (11:00 a.m. PDT).
During the event, Chief Executive Officer (CEO) Ben Lightburn will cover Filament’s overall business activities, intellectual property developments, and upcoming Phase I and II FDA clinical trials in partnership with the Translational Psychedelic Research Program at the University of California San Francisco, and recent intellectual property developments.
“We are incredibly proud of our progress thus far,” said Lightburn. “We are currently manufacturing GMP pharmaceutical-grade natural psilocybin extracts, and will soon begin the first ever FDA-approved clinical trials of natural psilocybin. We look forward to discussing this, and other exciting updates, during our virtual event.”
Director of Research, Ryan Moss, will also provide a virtual tour of Filament’s Research and Development Facility, where Filament’s wholly-owned subsidiary, Psilo Scientific, is currently manufacturing Good Manufacturing Practice (“GMP”) pharmaceutical-grade natural psilocybin extracts. These presentations will be followed by a question-and-answer session with the Company’s senior management team.
The event will be webcast live on Filament’s Investor Relations webpage, registration is required.
WHO: Ben Lightburn, CEO, and Ryan Moss, Director of Research
WHEN: Thursday, August 12, 2021 at 2:00 p.m. EST (11:00 a.m. PST)
WHERE: To access to the webcast, please pre-register here: https://bit.ly/3z7aF0V
An archived version of the webcast and presentation will be available on the investor relations section of the Company’s website following the event.
ABOUT FILAMENT HEALTH
Filament Health is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, and its wholly owned subsidiary Psilo Scientific’s in-house GMP facility and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on Canada’s NEO Exchange (NEO:FH).
Learn more at www.filament.health and on Twitter, LinkedIn and Instagram
MEDIA CONTACT
Anna Cordon, Director of Communications
778.245.9067
anna@filament.health
INVESTOR RELATIONS CONTACT
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s and TrPR’s ability to conduct clinical trials; the results of the partnership; the nature, timing, and possible success of Filament’s leading drug candidates and the impact and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
.jpg)
